Tango's vopimetostat combination shows 82% response rate in pancreatic cancer at ESMO 2026

What happened: Tango Therapeutics presented updated data from its ongoing Phase 1/2 study of vopimetostat combined with Revolution Medicines' daraxonrasib at the ESMO 2026 congress in Madrid (23 October 2026). In 22 efficacy-evaluable patients with second- or third-line MTAP-deleted, RAS-mutant pancreatic cancer, the combination achieved an objective response rate of 82%, median progression-free survival had not been reached, and 88% of patients were progression-free at 9 months.

How it works: Vopimetostat is a PRMT5 inhibitor — it blocks an enzyme that becomes a vulnerability in tumours that have lost the MTAP gene, which is deleted in roughly a quarter of pancreatic cancers. Daraxonrasib is an investigational drug that disables mutant RAS proteins, the most common drivers of pancreatic cancer. The two are being combined to attack both the tumour's addiction to PRMT5 and its RAS driver at the same time; the combination was generally well tolerated in the study.

Why it matters: Pancreatic cancer is one of the deadliest cancers and has few targeted treatment options, especially after chemotherapy has failed. The 82% response rate is unusually high for this setting, and the data strengthen the case for combining targeted drugs rather than using them one at a time. Tango plans to start a registrational Phase 3 trial of vopimetostat plus daraxonrasib in first-line MTAP-deleted pancreatic cancer in the first half of 2027 — a data-dependent expansion the market will be watching closely, since the response rate dipped from an earlier, smaller cohort and shares have been volatile around the readout.

Read more: Tango Therapeutics, 23 October 2026